Area of research
Pathology and Forensic Medicine · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Trametinib, Internal medicine, Oncology, Dabrafenib, and Hazard ratio.
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600/k </sub>mutant advanced or metastatic melanoma (MM).
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF<sub>V600E/K </sub>mutant advanced or metastatic melanoma (MM).